Syngene Extends Strategic Research Collaboration with Bristol Myers Squibb Until 2035

Syngene International Ltd, a leading contract research and manufacturing organization, has extended its strategic collaboration with Bristol Myers Squibb (BMS) through 2035. This milestone reflects the strength of their partnership, which began in 1998 and has evolved into one of the longest-standing collaborations in the global pharmaceutical industry.

The agreement broadens the scope of services across the drug development lifecycle, including discovery chemistry, biology, translational science, and clinical development support. Syngene’s dedicated research center for BMS in Bengaluru will continue to function as a ring-fenced facility, staffed by multidisciplinary scientists working exclusively on BMS programs.

Key Highlights:

• Extended Timeline: Collaboration now secured until 2035, marking nearly four decades of partnership.
• Scope of Work: Integrated services across drug discovery, development, and translational research.
• Dedicated Infrastructure: Exclusive research center in Bengaluru operating as an extension of BMS’s R&D.
• Strategic Impact: Reinforces Syngene’s position as a trusted global partner in pharmaceutical innovation.
• Patient-Centric Goal: Focus on advancing innovative therapies to improve global health outcomes.

This extension underscores Syngene’s commitment to scientific excellence and operational reliability, while strengthening India’s role in the global biopharma ecosystem.

Sources: InvestyWise, Syngene Annual Report 2025, Yahoo Finance